// App-Quantinova.ai

299.0 : Outcomes of patients with borderline-resectable pancreatic cancer treated with FOLFIRINOX versus gemcitabine plus nab-paclitaxel.

Researchers

Presenter

  • Shaina D'Lee Templeton

Principal Investigators

  • Michael Moser

  • Haji I. Chalchal

  • John Shaw

  • Yigang Luo

  • Adnan Zaidi

  • Shahid Ahmed

Medical Centers

  • College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada

  • Department of Surgery, University of Saskatchewan, Saskatoon, SK, Canada

  • Allan Blair Cancer Ctr, Regina, SK, Canada

  • Saskatchewan Cancer Agency, Saskatoon, Saskatchewan, Canada

  • University of Saskatchewan, Saskatoon, SK, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Pancreato-biliary malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Gemcitabine

  • Paclitaxel

  • FOLFIRINOX

Outcome

  • N/A

Study Design

  • Multicenteric

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved